OTC « Kline Blog on market data in energy, consumer products, healthcare, chemicals and specialty pesticides industries

Rx-to-OTC Switches Energize Solid OTC Drug Market Growth

Posted on April 3, 2012 by Kline Blogs

Rx-to-OTC switch brands continue to be major game changers on the OTC market, whether promoting strong gains or causing steep declines. Traditional OTC lines are delivering growth as they have expanded to meet consumer needs with the Centrum (Pfizer) and One-A-Day (Bayer) vitamin lines. Both of these lines using broad reaching marketing campaigns have had success with new product launches.

Filed under: Healthcare | Tagged: Advil, Aleve, Align, Alka-Seltzer, Allegra, Bayer, Bayer Aspirin, Caltrate, Centrum, Dayquil, Excedrin, GlaxoSmithKline, GSK, Johnson & Johnson, Little Remedies, Little Tummy, Luden's, Maalox, Metamucil, Nonprescription Drugs Market USA, Novartis, Nyquil, One-A-Day, OTC, over the counter drugs, Pediacare, Pfizer, Plan B, Prestige Brands, Procter & Gamble, RX-to-OTC, Sanofi-Aventis, Teva Pharmaceutical, Triaminic, Tylenol | Leave a Comment »

New Data Shows Plenty of Room for Innovators of All Sizes in OTC Market

Posted on December 7, 2010 by Laura Mahecha, Industry Manager - Healthcare

The over-the-counter drug market is heating up as consumers turn increasingly toward self-medication in an effort to minimize out-of-pocket healthcare costs. With increasing competition from private-label products, blockbuster switches, and somewhat unconventional entries into the OTC drug business, new data reveals that while innovation doesn’t necessarily equate to superb business performance, there is plenty of [...]

Filed under: Healthcare | Tagged: nonprescription drugs, nonprescription drugs market research, OTC, OTC drug business | Leave a Comment »

OTC Innovations Key to Ascending Above Price Comparisons and Private-Label Competition

Posted on May 29, 2009 by Laura Mahecha, Industry Manager - Healthcare

As we emerge from the global recession of 2008 and 2009, marketers of major OTC brands must be careful to continue to invest in innovations to bring new and improved OTCs to market. Several categories were hard hit by private-label competition as consumers were willing to trade down to less costly store brands during tough economic times. However, market share and sales for branded OTCs can be insulated from private-label competition by offering innovations such as fast-acting, fewer doses, improved drug delivery forms, faster healing times…

Filed under: Healthcare | Tagged: OTC, private label drugs | Leave a Comment »

Kline Blog on market data in energy, consumer products, healthcare, chemicals and specialty pesticides industries

Authors

Rx-to-OTC Switches Energize Solid OTC Drug Market Growth

New Data Shows Plenty of Room for Innovators of All Sizes in OTC Market

OTC Innovations Key to Ascending Above Price Comparisons and Private-Label Competition

Categories

Top Posts

Subscribe

Archives

energy, consumer products, chemicals, agriculture, pesticides, healthcare, OTC, consulting

Follow “Kline Blog on market data in energy, consumer products, healthcare, chemicals and specialty pesticides industries”